Literature DB >> 29139030

Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up.

Helga Raquel Garcia Ferrer1,2, Alexander Azan3, Isa Iraheta1, Joan Von Feldt3, Luis R Espinoza4, Julia Manasson5, Jose U Scher5, Abraham Garcia Kutzbach1,2, Alexis Ogdie6.   

Abstract

The objective of the study is to determine the risk factors for the development of reactive arthritis (ReA) and examine the factors associated with the persistence of symptoms. Patients with a new diagnosis of ReA and controls with a gastrointestinal (GI), urogenital, or sexually transmitted infection in the 3-6 months prior to study entry were prospectively enrolled in Guatemala City. ReA patients fulfilled the Assessment in Spondyloarthritis International Society criteria for peripheral spondyloarthropathy (SpA). Patients underwent history, examination, Achilles tendon ultrasound, and blood draw. Human leukocyte antigen (HLA) type and serum biomarkers were measured. t tests and nonparametric equivalents were used to examine the association of clinical, laboratory, and imaging factors with ReA. Patients were contacted 2 years later to assess for persistence of symptoms. Study subjects included patients with ReA (N = 32) and controls (N = 32). ReA patients were most frequently infected in April whereas controls were most frequently infected in August. Two ReA patients and two controls were HLA-B27-positive. Serum cathepsin K and C-reactive protein were higher in ReA patients compared to controls (p = 0.03 for both), while total cholesterol and low-density lipoprotein were lower (p = 0.008 and 0.045, respectively). Among those with ReA, 15 (47%) patients had continued symptoms at 2 years. These patients had a lower matrix metalloproteinase-3 level at diagnosis than patients for whom ReA resolved (p = 0.004). HLA-B27 was not associated with development of ReA in Guatemala; however, the month of infection was associated with ReA. The most striking finding was the persistence of arthritis at 2 years in nearly half of the patients.

Entities:  

Keywords:  Biomarkers; Epidemiology; Prognosis; Reactive arthritis; Risk factors; Spondyloarthropathy

Mesh:

Substances:

Year:  2017        PMID: 29139030      PMCID: PMC5776049          DOI: 10.1007/s10067-017-3911-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  36 in total

Review 1.  Ultrasound as an Outcome Measure in Gout. A Validation Process by the OMERACT Ultrasound Working Group.

Authors:  Lene Terslev; Marwin Gutierrez; Wolfgang A Schmidt; Helen I Keen; Emilio Filippucci; David Kane; Ralf Thiele; Gurjit Kaeley; Peter Balint; Peter Mandl; Andrea Delle Sedie; Hilde Berner Hammer; Robin Christensen; Ingrid Möller; Carlos Pineda; Eugene Kissin; George A Bruyn; Annamaria Iagnocco; Esperanza Naredo; Maria Antonietta D'Agostino
Journal:  J Rheumatol       Date:  2015-09-01       Impact factor: 4.666

2.  [Burden of salmonellosis and shigellosis in four departments of Guatemala, 2010].

Authors:  Sheilee L Díaz; Claudia Jarquin; Ana Judith Morales; Melissa Morales; Claudia Valenzuela
Journal:  Rev Panam Salud Publica       Date:  2015-10

Review 3.  Reactive arthritis.

Authors:  Timo Hannu
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-06       Impact factor: 4.098

4.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

5.  Soluble biomarkers may differentiate psoriasis from psoriatic arthritis.

Authors:  Vinod Chandran
Journal:  J Rheumatol Suppl       Date:  2012-07

6.  Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.

Authors:  Daniel Wendling; Jean-Pierre Cedoz; Evelyne Racadot
Journal:  Joint Bone Spine       Date:  2008-10       Impact factor: 4.929

7.  Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study.

Authors:  J M Townes; A A Deodhar; E S Laine; K Smith; H E Krug; A Barkhuizen; M E Thompson; P R Cieslak; J Sobel
Journal:  Ann Rheum Dis       Date:  2008-02-13       Impact factor: 19.103

8.  Follow-up study of Reiter's disease and reactive arthritis. Factors influencing the natural course and the prognosis.

Authors:  M Leirisalo-Repo; G Skylv; M Kousa
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

9.  Obesity and the risk of psoriatic arthritis: a population-based study.

Authors:  Thorvardur Jon Love; Yanyan Zhu; Yuqing Zhang; Lindsay Wall-Burns; Alexis Ogdie; Joel M Gelfand; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2012-05-14       Impact factor: 19.103

Review 10.  Epidemiology of spondyloarthritis.

Authors:  Carmen Stolwijk; Annelies Boonen; Astrid van Tubergen; John D Reveille
Journal:  Rheum Dis Clin North Am       Date:  2012-08       Impact factor: 2.670

View more
  4 in total

Review 1.  Reactive arthritis: update 2018.

Authors:  A García-Kutzbach; J Chacón-Súchite; H García-Ferrer; I Iraheta
Journal:  Clin Rheumatol       Date:  2018-02-17       Impact factor: 3.650

Review 2.  Expanding the spectrum of reactive arthritis (ReA): classic ReA and infection-related arthritis including poststreptococcal ReA, Poncet's disease, and iBCG-induced ReA.

Authors:  Yoshinori Taniguchi; Hirofumi Nishikawa; Takeshi Yoshida; Yoshio Terada; Kurisu Tada; Naoto Tamura; Shigeto Kobayashi
Journal:  Rheumatol Int       Date:  2021-05-01       Impact factor: 2.631

3.  Approaching Reactive Arthritis Associated With Poor Prognostic Factors: A Case Report and Literature Review.

Authors:  Swetha Ann Alexander; Eunjung Kim; Ranadeep Mandhadi
Journal:  Cureus       Date:  2021-02-25

4.  Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.

Authors:  Kuo-Tung Tang; Bo-Chueh Hsu; Der-Yuan Chen
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.